Ibrx stock price forecast the IBRX stock price forecast is

The IBRX stock price forecast is benefiting from biotech M&A speculation. Potential strategic partnerships could significantly boost perceived valuation, pushing target prices nearer to $7. As for the current policy rate, Bullard emphasized that the Fed is in great shape to keep rates steady and must wait for inflation data before any decisions have been made. He added that if inflation is sticky at where "it is right now" then a rate cut in 2025 is highly unlikely. On the flipside, he suggested that if inflation begins to rise again, the Fed may raise rates again. ImmunityBio is doing well on the financial side, as in Q3 2024, it made $6.0 million in product revenue, six times more than last quarter and outperforming analysts’ predictions. Starting January 2025, ANKTIVA has a permanent J-code, making it easier for Medicare and VA patients to get covered. ImmunityBio, Inc. (NASDAQ:IBRX) is also expanding globally, having applied for approval in the UK’s MHRA last November and planning for an EMA in the EU soon. Technical chartists following IBRX stock price forecast models highlight a bullish pennant formation. If confirmed by volume spikes, upside targets cluster between $6.40–$6.85 within a six-week horizon.